Early adopters of weight-loss drugs have tended to be wealthy because ... They’re thinking about inventory management, how to shift the size curve downward.” Before Handler lost 50 pounds on Zepbound, ...

Pharmaceutical giant Eli Lilly (LLY) is putting $4.5 billion toward building a new site to develop and manufacture drugs.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

The popular weight-loss and diabetes medication tirzepatide is no longer in short supply, the Food and Drug Administration said. Eli Lilly's tirzepatide, sold as Zepbound for weight loss and ...

Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Drugs prescribed for weight loss, such as Mounjaro, Ozempic, Wegovy, and Zepbound, have been popular, expensive, and in short supply. To meet the demand, health providers like Hims & Hers had ...